Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a multiple-dose study, conducted by Kyowa Hakko Kirin Pharma, Inc. (KKP), of the investigational anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) stock performance was 0.09% in last session and finished the day at $45.48. Traded volume was 199,869.00million shares in the last session and the average volume of the stock remained 179.81K shares. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) insider ownership is 2.90%.

Sorrento Therapeutics Inc (NASDAQ:SRNE) will use its linking technology to combine chemotherapeutic agents with Morphotek antibodies in order to generate and develop antibody-drug conjugates (ADCs), in a deal that could net Sorrento up to $50 million tied to unspecified milestones. Sorrento Therapeutics Inc (NASDAQ:SRNE) rose 7.79 percent to $6.64 Wednesday on volume of 222,005.00million shares. The intra-day range of the stock was $6.13 to $6.67. Sorrento Therapeutics Inc (NASDAQ:SRNE) has a market capitalization of $153.07million.

Five Prime Therapeutics, Inc (NASDAQ:FPRX) held its annual meeting of stockholders (the “Annual Meeting”) on May 16, 2014. The final results for each of the proposals submitted to a vote of company’s stockholders at the Annual Meeting are set forth below. The proposals set forth below are described in detail in company’s definitive proxy statement filed with the Securities and Exchange Commission on April 4, 2014. (i) Company’s stockholders elected all of the nominees for Class I directors to serve a three-year term until the 2017 Annual Meeting, or until their respective successors are duly elected and qualified. (ii) Company’s stockholders ratified the appointment of Ernst & Young LLP as Five Prime Therapeutics, Inc (NASDAQ:FPRX)’s independent registered public accounting firm for the fiscal year ending December 31, 2014. Five Prime Therapeutics Inc (NASDAQ:FPRX)’s stock on June 25, 2014 reported a increase of 4.44% to the closing price of $15.07. Its fifty two weeks range is $8.02 -$23.33. The total market capitalization recorded $323.08million. The overall volume in the last trading session was 242,806.00million shares. In its share capital, FPRX has 21.44million outstanding shares.

Aratana Therapeutics Inc(NASDAQ:PETX) Insider Linda Rhodes sold 4,626 shares of the company’s stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $15.00, for a total value of $69,390.00. Following the completion of the transaction, the insider now directly owns 456,305 shares of the company’s stock, valued at approximately $6,844,575. On Wednesday, shares of Aratana Therapeutics Inc (NASDAQ:PETX) dropped -5.43% to close the day at $14.79. Company return on investment (ROI) is -4.20% and its monthly performance is recorded as 12.64%. Aratana Therapeutics Inc (NASDAQ:PETX) quarterly revenue growth is -21.54%.

On June 6, 2014, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Pain Therapeutics, Inc. (NASDAQ:PTIE) approved changes in compensation for the Company’s named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission) with respect to the officers’ and the Company’s performance from mid-2013 to mid-2014. Pain Therapeutics, Inc. (NASDAQ:PTIE) stock performance was 3.00% in last session and finished the day at $5.84. Traded volume was 333,804.00million shares in the last session and the average volume of the stock remained 253.95K shares. The beta of the stock remained 0.93. Pain Therapeutics, Inc. (NASDAQ:PTIE) insider ownership is 1.80%.